Leading structural heart company Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has presented positive news about its DurAVR™ Transcatheter Heart Valve (THV) at the New York Valves 2024 Conference, held at the Jacob K. Javits Convention Center in New York City.
Dr Anita Asgar from the Institut de Cardiologie de Montreal presented a series of cases involving five high-risk patients who underwent valve-in-valve (ViV) procedures using DurAVR™ THV.
These patients were treated under Health Canada’s Special Access Program (SAP), which permits the use of unlicensed medical devices in emergencies when conventional therapies are unsuitable or unavailable.
New valve within a failing valve
While Transcatheter Aortic Valve Replacement (TAVR) procedures have revolutionised heart valve replacement, up to 30% of patients may eventually require a second valve due to the deterioration of the first implant.
Transcatheter ViV replacement is complex, involving the implantation of a new heart valve within a failing bioprosthetic aortic valve. It’s less invasive than reoperative surgical aortic valve replacement but still presents unique challenges.
“Valve-in-valve procedures often force us to make difficult choices,” explained Dr Asgar. “Current TAVR devices may limit optimal valve function (haemodynamics) for these very sick patients, while others are operationally challenging to ensure access to coronary arteries.”
Anteris shares have been as much as 3.58% higher in ASX trading this morning to A$19.99
Restoring valve haemodynamics
The ViV implantation using DurAVR™ THV significantly reduced aortic valve gradients to levels similar to the initial post-surgical valve gradient.
Key results from the series of five cases include:
- post-surgical valve replacement gradient (8 to 13 years prior): 13.82 mmHg;
- mean gradient prior to ViV: 58.60 mmHg; and
- 30-day core lab echo data post DurAVR™ ViV: 13.76 mmHg.
No major complications were reported.
Dr Asgar noted, “This data set of valve-in-valve patients highlights the impact of the DurAVR™ valve biomimetic design by restoring these patients’ haemodynamics to the performance of their initial surgical valve and is very encouraging for the wave of valve-in-valve patients that are coming in the future.”
About Anteris Technologies
Anteris Technologies, headquartered in Australia with significant operations in Minneapolis, USA, is dedicated to designing, developing and commercialising innovative medical devices.
The company’s lead product, DurAVR™ THV, is a transcatheter heart valve designed for treating aortic stenosis.
DurAVR™ THV uses a single piece of bioengineered tissue, mimicking the performance of a healthy human aortic valve.
This unique valve is made with ADAPT® tissue, Anteris’ patented anti-calcification technology, clinically used for more than 10 years in more than 55,000 patients worldwide.
Anteris Technologies’ mission is to revolutionise the structural heart market with clinically superior solutions addressing significant unmet clinical needs.